Fig. 1From: One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry studyFlow-chart of patients from inclusion to study end with initial evaluation at baseline (M0) and evaluation at month 3 (M3), month 6 (M6), month 9 (M9) and month 12 (M12)Back to article page